BD 广度深度双提升，当下站在估值重塑起点——先声药业更新报告

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [7]. Core Insights - The company has achieved significant business development (BD) progress, enhancing both the breadth and depth of its self-developed new drugs. Recent collaborations with major pharmaceutical companies indicate a strong pipeline and potential for revenue growth [4]. - The financial forecast predicts total revenue growth from 66.40 billion CNY in 2023 to 104.27 billion CNY by 2027, with a compound annual growth rate (CAGR) of approximately 16% [4][6]. - The net profit attributable to shareholders is expected to rise from 7.15 billion CNY in 2023 to 16.09 billion CNY in 2027, reflecting a significant increase in profitability [4][6]. Financial Summary - Revenue projections for the company are as follows: 6,640 million CNY in 2023, 6,635 million CNY in 2024, 7,690 million CNY in 2025, 9,009 million CNY in 2026, and 10,427 million CNY in 2027, with year-over-year growth rates of 4%, 0%, 16%, 17%, and 16% respectively [3][4]. - The net profit forecast shows a decline of 23% in 2023, followed by a recovery with growth rates of 3%, 63%, 16%, and 16% in the subsequent years [3][4]. - Earnings per share (EPS) are projected to increase from 0.28 CNY in 2023 to 0.62 CNY in 2027, indicating a positive trend in shareholder returns [3][4]. Business Development Highlights - The company has secured multiple partnerships, including a recent agreement with AbbVie for clinical development collaboration, which includes a payment of 40 million USD [4]. - A licensing agreement with Boehringer Ingelheim for a dual-specific antibody is expected to generate up to 1.016 billion EUR in milestone payments, showcasing the company's strong position in the market [4]. - The company is also advancing its ADC (antibody-drug conjugate) pipeline, with significant collaborations that enhance its competitive edge in the industry [4].